Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425904 · ClinicalTrials.gov registry record · Phase 2
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 15
- Study locations
NCT02425904: Active Phase 2 study of Langerhans Cell Histiocytosis, sponsored by Dana-Farber Cancer Institute.
NCT02425904 is a Phase 2 study of Langerhans Cell Histiocytosis that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants, below the 1,136-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (98% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02425904, a Phase 2 study of Langerhans Cell Histiocytosis, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 15
- Study locations
Study Summary
This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
Primary Outcome
The OR was defined as the proportion of participants achieving certain response on treatment among LCH patients, criteria were defined per protocol. Better response were defined as achieving complete disease resolution (NAD) or disease regression (AD better); intermediate response defined as stable or unchanged disease status; worse response defined as disease progression.
Conditions Studied
Interventions
- DRUG Clofarabine
Study Locations (15)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Dana-Farber Cancer Institute - Boston
California
- Children's Hospital of Los Angeles - Los Angeles
- University of California San Francisco Medical Center - San Francisco
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
District of Columbia
- Children's National Medical Center - Washington D.C.
New York
- Mount Sinai Medical Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- The Children's Hospital of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-05 |
| Est. Completion | 2026-07-30 |
| Phase | Phase 2 |
What the registry record for NCT02425904 still lists
NCT02425904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,136-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 1 intervention - of which Clofarabine is the first listed.
NCT02425904 lists 15 locations in 11 states (Massachusetts, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT02425904 about?
NCT02425904 is a clinical study titled "Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders". This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
What is the current status of trial NCT02425904?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-05. Estimated completion is 2026-07-30.
What conditions does trial NCT02425904 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT02425904?
The interventions under investigation include: Clofarabine (DRUG).
Who is sponsoring clinical trial NCT02425904?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02425904 being conducted?
This trial has 15 study locations across Arizona, Arkansas, California, District of Columbia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02425904's enrollment target sits among peer trials
25 7th of 8 higher than 2 of 8 other Langerhans Cell Histiocytosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Langerhans Cell Histiocytosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
COMPLETED · Phase 2
-
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia